Patents show all

OXiGENE has 1 licensable patents.
102Applications58Issued

Clinical Trials show all

1Phase 21Phase 2/Phase 3

SEC Filings show all

8-K23210-Q6510-K21D2S-11

SEC Form D Funding Events

DateOfferedSoldType
2010-03-26$7,500,000$7,500,000Equity, Option to Acquire
2008-11-04UnknownUnknownOther (Paper Filing)

Key Executives

  • Peter J. Langecker
    Executive Officer
  • William N. Shiebler
    Director
  • James B. Murphy
    Executive Officer
  • Roy H. Fickling
    Director
  • William D. Schwieterman
    Director
  • Mark Kessel
    Director
  • Alastair J.j. Wood
    Director
  • David Chaplin
    Executive Officer, Director